As of Feb 21, 2025, Vertex Pharmaceuticals Incorporated's fair value using the Peter Lynch formula is ($30.5) per share. The current price of $484.2 suggests Vertex Pharmaceuticals Incorporated may be overvalued by this metric.

What is Vertex Pharmaceuticals Incorporated Price to Earnings (P/E) ratio?

As of Feb 21, 2025, Vertex Pharmaceuticals Incorporated's P/E ratio is (232.8x). This is calculated by dividing the current share price of $484.2 by the Earnings per Share (EPS) for the trailing twelve months, which is ($2.1). The P/E ratio indicates how much investors are willing to pay for each dollar of earnings.

What is Vertex Pharmaceuticals Incorporated earnings per share (EPS)?

Vertex Pharmaceuticals Incorporated earnings per share (EPS) for the twelve months ending Feb 21, 2025, was ($2.1), a 14.7% growth year-over-year.